Yi Hu - School of Medicine, Nankai University;Chinese PLA General Hospital

基本信息

Career Trajectory

Bio

学术兼职

1. 中央保健委员会会诊专家

2.中央军委保健委员会会诊专家

3.中国研究型医院学会分子肿瘤学及免疫治疗专业委员会主任委员

4.北京乳腺病防治学会对外合作部主任及国际医疗与合作专业委员会名誉主任

5.北京乳腺病防治学会肿瘤免疫治疗专业委员会主任委员

6.中国研究型医院学会肿瘤专业委员会副主任委员

7.中国宋庆龄基金会肿瘤医疗及产学研联盟副理事长

8.中华医学生物免疫学会常务理事

9.国家自然科学基金委员会评审专家

10.全国医师定期考核肿瘤专业编辑委员会委员

11.《中国肿瘤临床》杂志的审稿专家

Research Interests

Papers共 386 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

A Multicenter, Real‐world Study on Effectiveness and Safety of First‐line Modified PD‐1 Inhibitors with Chemotherapy in Advanced Non‐small Cell Lung Cancer (ansclc) with Drive Gene‐negative

Tao Li, Chao Chen,Lu Liu,Jiapei Qin,Lupeng Qiu, An Wang,Weiwei Dong, Gehan Zhang,Yao Li,Lei Zhao, Fan Zhang,Yi Hu

CANCER MEDICINE（2024）

Cited0Views0WOSBibtex

The Efficacy of Pemigatinib in Advanced NSCLC with FGFR Aberration: Case Report

Ming Gao,Lijie Wang,Fangfang Jing,Fan Zhang,Haitao Tao,Yi Hu

CLINICAL LUNG CANCERno. 1 (2024): e62-e66

Cited0Views0WOSBibtex

Low-dose Chemotherapy Combined with Delayed Immunotherapy in the Neoadjuvant Treatment of Non-Small Cell Lung Cancer and Dynamic Monitoring of the Drug Response in Peripheral Blood

Chaoyang Liang,Qi Song, Wenhao Zhou, Na Li,Qi Xiong,Chaohu Pan,Shaohong Zhao, Xiang Yan, Xiaoling Zhang,Yaping Long,Juntang Guo, Tao Wang,Weiwei Shi,Shengjie Sun,Bo Yang,Zhouhuan Dong,Haitao Luo,Jie Li,Yi Hu

medrxiv（2024）

Cited0Views0Bibtex

Rechallenge of Immune Checkpoint Inhibitors in Advanced Non‐small Cell Lung Cancer

Gen Lin,Zhijie Wang,Qian Chu,Yi Hu,Dingzhi Huang,Jun Wang,Fan Yang,Wenzhao Zhong,Chengzhi Zhou,Bo Zhu,Xinghao Ai,Baoshan Cao,Yabing Cao,Mingqiu Chen,Xiaohui Chen,Tianqing Chu,Jianchun Duan,Yun Fan,Yong Fang,Shuitu Feng,Weineng Feng,Hui Guo,Chengbo Han,Yong He,Shaodong Hong,Jie Hu,Meijuan Huang,Yan Huang,Da Jiang,Kan Jiang,Richeng Jiang,Bo Jin,Shi Jin,Jisheng Li,Min Li,Ziming Li,Chao Li,Jie Lin,Anwen Liu,Si-Yang Maggie Liu,Liu Yutao,Zhefeng Liu,Zhe Liu,Zhenhua Liu,Zhentian Liu,Zhigang Liu, Yuping Lu,Tangfeng Lv,Zhiyong Ma,Qian Miao,Min Peng,Xingxiang Pu,Xiu Bao Ren,Jianzhen Shan,Jinlu Shan,Peng Shen,Bo Shen,Meiqi Shi,Yong Song,Zhengbo Song,Chunxia Su,Jianguo Sun,Panwen Tian,Jinliang Wang,Feng Wang,Huijuan Wang,Jialei Wang,Qian Wang,Wenxian Wang,Yan Wang,Lin Wu,Fang Wu,Yang Xia,Congying Xie,Conghua Xie,Tao Xin,Jianping Xiong,Haipeng Xu,Song Xu,Yiquan Xu,Bin Xu,Chunwei Xu,Xiaolong Yan,Zhenzhou Yang,Wenxiu Yao,Yao Yu,Ye Feng,Zongyang Yu,Yongfeng Yu,Dongsheng Yue,Haibo Zhang,Hongmei Zhang,Li Zhang,Longfeng Zhang,Qiuyu Zhang,Tongmei Zhang,Bicheng Zhang,Jun Zhao,Mingfang Zhao,Xiaobin Zheng,Qiaofeng Zhong,Jin Zhou,Penghui Zhou,Zhengfei Zhu,Juntao Zou,Zihua Zou

THORACIC CANCER（2024）

Cited0Views0WOSBibtex

Establishment and Validation of a Clinicopathological Prediction Model for Postoperative Recurrence of Stage IA Lung Adenocarcinoma

Xin Zhang,Jie Yang,Shining Li,Yong Ao,Leqi Zhong,Xinyu Liu,Kongjia Luo,Yi Hu

JOURNAL OF THORACIC DISEASEno. 5 (2024): 3061-3074

Cited0Views0WOSBibtex

Surufatinib Plus PD-1/L1 Inhibitors As Maintenance Therapy Following First Line (1L) Platinum-Based Chemotherapy Combined with PD-1/L1 Inhibitors in Patients (pts) with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Yi Hu,Jianhua Chen, Dongqing Lv,Jinliang Wang, Junxun Ma, Tienan Yi,Shikai Wu, Xiangdong Zhou, Xingxing Zhang, Dongmei Chen,Songhua Fan,Michael Shi,Weiguo Su

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Efficacy and Safety of IBI351 Monotherapy in KRASG12C-Mutated Metastatic Colorectal Cancer: Results from a Pooled Analysis of Phase I Part of Two Studies

Ying Yuan,Yanhong Deng, Yongdong Jin,Zeng-Qing Guo,Yueyin Pan,Cunji Wang,Zhiwu Wang,Yi Hu,Dong Hua, Xiangjiao Meng, Zhiye Zhang, Mingfang Zhao,Xiaorong Dong,Dingzhi Huang, Xiaoyan Li,Lian Liu, Meili Sun,Huijuan Wang,Xiuwen Wang,Nong Yang,Mingjun Zhang,Sheng Hu, Dongde Wu, Jingjing Huang,Sujie Zhang,Mengna Huang,Ke-feng Ding

crossref（2024）

Cited0Views0Bibtex

Comparative Efficacy of Six Programmed Cell Death Protein-1 Inhibitors As First-Line Treatment for Advanced Non-Small Cell Lung Cancer: a Multicenter Retrospective Cohort Study

Siyuan Chen,Yuhui Qin,Zhijuan Du, Yu Qiao,Yi Hu,Zhefeng Liu

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0WOSBibtex

Systematic Pan-Cancer Analysis Identified RASSF1 As an Immunological and Prognostic Biomarker and Validated in Lung Cancer

Yibing Bai,Yuanyong Wang,Jiapei Qin,Ting Wang, Xin Zhou, Zhiqiang Ma, An Wang,Wenyu Yang,Jinliang Wang,Jinfeng Li,Yi Hu

HELIYON（2024）

Cited0Views0WOSBibtex

Prognosis of Immune Checkpoint Inhibitor-Related Myocarditis: Retrospective Experience of a Single Institution

Yuhui Qin, Teng Zhang,Zhijuan Du,Siyuan Chen, Yanan Li, Yahui Lv, Xiangyu Du,Yi Hu,Zhefeng Liu

INTERNATIONAL IMMUNOPHARMACOLOGY (2024)

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Yi Hu(胡毅)

Professor

Papers共 386 篇Author StatisticsCo-AuthorSimilar Experts